Scott Evans

13.1k total citations · 4 hit papers
194 papers, 6.5k citations indexed

About

Scott Evans is a scholar working on Statistics and Probability, Epidemiology and Economics and Econometrics. According to data from OpenAlex, Scott Evans has authored 194 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Statistics and Probability, 44 papers in Epidemiology and 44 papers in Economics and Econometrics. Recurrent topics in Scott Evans's work include Statistical Methods in Clinical Trials (50 papers), Health Systems, Economic Evaluations, Quality of Life (40 papers) and Antibiotic Resistance in Bacteria (28 papers). Scott Evans is often cited by papers focused on Statistical Methods in Clinical Trials (50 papers), Health Systems, Economic Evaluations, Quality of Life (40 papers) and Antibiotic Resistance in Bacteria (28 papers). Scott Evans collaborates with scholars based in United States, Japan and Spain. Scott Evans's co-authors include David B. Clifford, Ronald J. Ellis, Vance G. Fowler, Justin C. McArthur, Kunling Wu, Ronald J. Bosch, Robert A. Bonomo, Ann C. Collier, Yijun Yang and Dean Follmann and has published in prestigious journals such as New England Journal of Medicine, Journal of Personality and Social Psychology and SHILAP Revista de lepidopterología.

In The Last Decade

Scott Evans

180 papers receiving 6.3k citations

Hit Papers

The prevalence and incidence of neurocognitive impairment... 2007 2026 2013 2019 2007 2017 2020 2022 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The prevalence and incidence of neurocognitive impairment in the HAART era
    2007 504 citations Scott Evans, Ronald J. Ellis et al. AIDS profile →
  2. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
    2017 479 citations Vance G. Fowler, Scott Evans et al. Clinical Infectious Diseases profile →
  3. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA
    2020 304 citations S. Claiborne Johnston, Pierre Amarenco et al. profile →
  4. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children
    2022 80 citations Vance G. Fowler, Henry F. Chambers et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Evans United States 40 1.9k 1.9k 1.6k 1.3k 1.1k 194 6.5k
Dean Follmann United States 42 1.0k 0.5× 1.1k 0.6× 1.8k 1.1× 429 0.3× 65 0.1× 170 10.5k
Robert Gross United States 47 1.8k 0.9× 4.2k 2.3× 2.0k 1.3× 876 0.7× 60 0.1× 265 7.9k
Andrew Nunn United Kingdom 58 621 0.3× 4.9k 2.6× 3.4k 2.2× 342 0.3× 156 0.1× 246 11.7k
B. Frank Polk United States 46 1.9k 1.0× 2.7k 1.4× 3.6k 2.3× 833 0.6× 118 0.1× 93 9.2k
Christian Pradier France 43 2.3k 1.2× 4.0k 2.1× 2.6k 1.7× 3.5k 2.7× 108 0.1× 204 8.2k
David W. Haas United States 50 3.1k 1.6× 4.6k 2.5× 2.0k 1.3× 1.4k 1.1× 74 0.1× 212 8.7k
Sotirios Tsiodras Greece 50 462 0.2× 4.1k 2.2× 2.3k 1.5× 837 0.6× 574 0.5× 316 9.7k
Rodolphe Thiébaut France 42 2.2k 1.2× 3.3k 1.8× 1.7k 1.1× 2.6k 2.0× 60 0.1× 178 7.5k
André Charlett United Kingdom 51 150 0.1× 3.3k 1.7× 2.6k 1.7× 168 0.1× 227 0.2× 275 9.7k
Motomi Mori United States 53 131 0.1× 913 0.5× 1.7k 1.1× 273 0.2× 104 0.1× 157 9.0k

Countries citing papers authored by Scott Evans

Since Specialization
Citations

This map shows the geographic impact of Scott Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Evans more than expected).

Fields of papers citing papers by Scott Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Evans. The network helps show where Scott Evans may publish in the future.

Co-authorship network of co-authors of Scott Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Evans. A scholar is included among the top collaborators of Scott Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Evans. Scott Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Howard‐Anderson, Jessica, Sarah B. Doernberg, Dennis O. Dixon, et al.. (2025). Interagency Collaboration for Patient-Centered Antibacterial Drug Development. Clinical Infectious Diseases. 81(Supplement_1). S11–S15.
2.
3.
Johnston, S. Claiborne, Ritika Jain, Pierre Amarenco, et al.. (2023). Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial. BMJ Neurology Open. 5(2). e000478–e000478.
4.
Chamberlain, James M., Jaideep Kapur, Robert Silbergleit, et al.. (2023). Desirability of Outcome Ranking for Status Epilepticus. Neurology. 101(16). e1633–e1639. 4 indexed citations
5.
Komarow, Lauren, Damon W. Ellison, Andrey A. Filippov, et al.. (2023). Interlaboratory comparison of Pseudomonas aeruginosa phage susceptibility testing. Journal of Clinical Microbiology. 61(12). e0061423–e0061423. 10 indexed citations
6.
Johnston, S. Claiborne, Pierre Amarenco, Hans Denison, et al.. (2021). Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke. 52(11). 3482–3489. 11 indexed citations
7.
Evans, Scott. (2021). Waking up to p : Comment on “The Role of p -Values in Judging the Strength of Evidence and Realistic Replication Expectations”. Statistics in Biopharmaceutical Research. 13(1). 19–21. 1 indexed citations
8.
9.
Claeys, Kimberly C., Richard T. Smith, Yunyun Jiang, et al.. (2021). Day at the Races: Comparing BioFire FilmArray Blood Culture ID Panels With Verigene Blood Culture Panel in Gram-Negative Bloodstream Infections Using DOOR-MAT Analysis. Clinical Infectious Diseases. 73(6). 1103–1106. 11 indexed citations
10.
Evans, Scott, Mikael Knutsson, Pierre Amarenco, et al.. (2020). Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. Clinical Trials. 17(6). 617–626. 13 indexed citations
11.
Easton, J. Donald, Hans Denison, Scott Evans, et al.. (2019). Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. International Journal of Stroke. 14(9). 908–914. 6 indexed citations
12.
Sugimoto, Tomoyuki, Toshimitsu Hamasaki, Scott Evans, & Susan Halabi. (2019). Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes. Lifetime Data Analysis. 26(2). 266–291. 3 indexed citations
13.
Evans, Scott, Daniel B. Rubin, John H. Powers, & Dean Follmann. (2018). Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?. PubMed. 10(1). 4 indexed citations
14.
Gewandter, Jennifer S., Michael McDermott, Scott Evans, et al.. (2017). Interpretation of CIs in clinical trials with non-significant results: systematic review and recommendations. BMJ Open. 7(7). e017288–e017288. 21 indexed citations
15.
Evans, Scott & John H. Powers. (2017). Evaluating Anti-infective Drugs in the Resistant Pathogen Setting: Can We Use External Controls?. PubMed. 9(1). 1 indexed citations
16.
Nakasujja, Noeline, Sachiko Miyahara, Scott Evans, et al.. (2012). Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology. 80(2). 196–202. 50 indexed citations
17.
Robertson, K. R., Zhaohui Su, David M. Margolis, et al.. (2010). Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 74(16). 1260–1266. 167 indexed citations
18.
Zhao, Yu, Bradford Navia, Christina M. Marra, et al.. (2010). Memantine for AIDS Dementia Complex: Open-Label Report of ACTG 301. HIV Clinical Trials. 11(1). 59–67. 2 indexed citations
19.
Evans, Scott & Steven P. Nichols. (2007). An integrated education and technology commercialization program: the idea to product® competition and related courses. International journal of engineering education. 23(3). 527–535. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dean Follmann Breakdown of academic impact, for papers by Robert Gross Breakdown of academic impact, for papers by Andrew Nunn Breakdown of academic impact, for papers by B. Frank Polk Breakdown of academic impact, for papers by Christian Pradier Breakdown of academic impact, for papers by David W. Haas Breakdown of academic impact, for papers by Sotirios Tsiodras Breakdown of academic impact, for papers by Rodolphe Thiébaut Breakdown of academic impact, for papers by André Charlett Breakdown of academic impact, for papers by Motomi Mori
Rankless by CCL
2026